Article

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

2019-01-01

Abstract excerpt

Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months. However, over the last decade, improved understanding of driver mutations, especially identification of epidermal growth factor receptor (EGFR) mutation, has changed the treat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 716e5018-0797-5157-aa01-e79149c7502d
DOI: 10.4103/crst.crst_51_19

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementDOI 10.4103/crst.crst_51_19Read

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.Semantic proximity Read

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read

Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations.Semantic proximity Read

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read

Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.Semantic proximity Read

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.Semantic proximity Read

Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer.Semantic proximity Read

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.Semantic proximity Read

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.Semantic proximity Read

Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read

Paradigm shift in the management of metastatic Non-small Cell Lung CancerSemantic proximity Read